The U.S. Human Papillomavirus (HPV) vaccine market was valued at USD 2.76 billion in 2022 and is projected to reach USD 4.05 billion by 2030, growing at a CAGR of 4.9% between 2023 and 2030. Several factors contribute to the market’s expansion, including increased awareness of HPV vaccination, the rising incidence of cervical cancer and other HPV-related diseases, government-led vaccination campaigns, advancements in vaccine technology, a stronger focus on cancer prevention, and increased healthcare spending.
As a leader in healthcare innovation, the U.S. has recognized the significance of HPV vaccination in preventing cervical cancer and related illnesses, leading to greater demand. Government-backed initiatives aim to expand vaccine coverage, while technological advancements have enhanced the effectiveness and safety of HPV vaccines. The combination of heightened awareness, government support, technological progress, and the urgent need for disease prevention continues to drive market growth.
Click – https://www.marketsandata.com/industry-reports/united-states-ventilator-market
High Prevalence of HPV-Related Diseases
The widespread occurrence of HPV-related diseases is a key factor fueling the growth of the HPV vaccine market in the U.S. HPV is the most common sexually transmitted infection, with approximately 42.5 million individuals in the U.S. affected by at least one HPV strain capable of causing precancers, cancers, or anogenital warts in 2018. Additionally, around 13 million new infections were recorded that year. The overall HPV infection rate stood at 40%, with 41.8% in males and 38.4% in females. Disease-associated HPV infections affected 24.2% of males and 19.9% of females, with nearly 23.4 million individuals infected by high-risk HPV strains in 2018. The high infection rate underscores the importance of widespread HPV vaccination.
Increasing Awareness of HPV and the Vaccine
A study published on ScienceDirect analyzed trends in HPV and HPV vaccine awareness among U.S. adults from 2008 to 2018 using data from five HINTS surveys. The study found that HPV awareness in the U.S. was higher than in many other countries. However, after an initial increase from 65% in 2008 to 67% in 2013, awareness declined, reaching 60% by 2018. The decrease was particularly noticeable among males, individuals with lower education levels, and lower-income groups. The study also highlighted disparities in awareness among racial and ethnic minorities, rural populations, older adults (65+), and individuals with household incomes below $35,000. Despite these disparities, increasing awareness has significantly contributed to the growth of the HPV vaccine market in the U.S.
Government Initiatives Driving HPV Vaccination
The U.S. government has implemented various initiatives to promote HPV vaccination and reduce HPV-related diseases. These efforts focus on education, accessibility, and cost-effectiveness to increase vaccination rates and improve public health. The Centers for Disease Control and Prevention (CDC) administers the Vaccines for Children (VFC) Program, which provides free HPV vaccines to eligible healthcare providers for uninsured and Medicaid-covered children under 18. Additionally, healthcare providers receive administration fees from the Centers for Medicare and Medicaid Services (CMS) for vaccine delivery. These government programs play a vital role in expanding HPV vaccine coverage and market growth.
Rising Demand for HPV Vaccination for Head and Neck Cancer
The increasing demand for HPV vaccines to prevent head and neck cancers is shaping market dynamics. The healthcare industry recognizes vaccination as a proactive strategy to reduce the risk of these cancers. For instance, in June 2020, Merck & Co., Inc. received FDA approval for the expanded use of GARDASIL9, which now includes the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. This expansion reflects the growing role of HPV vaccines in broader cancer prevention efforts.
Growing Use of Quadrivalent HPV Vaccines
The demand for quadrivalent HPV vaccines has contributed to market growth. This vaccine formulation includes four HPV type-specific virus-like particles (VLPs) derived from HPV types 6, 11, 16, and 18, combined with an aluminum adjuvant. Clinical trials have demonstrated its high effectiveness in preventing persistent HPV infections and precursor lesions leading to cervical, vaginal, and vulvar cancers, as well as genital warts. In November 2022, Merck released an updated global analysis on the impact of GARDASIL, highlighting its effectiveness in reducing high-grade (precancerous) and low-grade cervical abnormalities, as well as HPV infection rates in both men and women.
Impact of COVID-19 on the HPV Vaccine Market
The COVID-19 pandemic significantly affected HPV vaccination rates in the U.S. A model-based analysis published by the National Center for Biotechnology Information (NCBI) examined vaccine coverage before and during the pandemic, revealing a decline in vaccine administration between March and August 2020 compared to 2018–2019 levels. The model projected that, without recovery in vaccination rates, an estimated 130,853 to 213,926 additional cases of genital warts, 22,503 to 48,157 cases of CIN1, 48,682 to 110,192 cases of CIN2/3, and 2,882 to 6,487 cases of cervical cancer could occur over the next century. The pandemic emphasized the need for sustained HPV vaccination efforts to prevent long-term health consequences.
Market Report Overview
The report “United States Human Papillomavirus Vaccine Market Assessment, Opportunities, and Forecast, 2016-2030F” by Market Xcel provides an in-depth analysis of the U.S. HPV vaccine market. It covers market size, segmental shares, growth trends, COVID-19 impact, emerging opportunities, and forecasts for 2023–2030. Additionally, the report profiles leading industry players, detailing their market share, business strategies, and competitive landscape.
Contact
Mr. Vivek Gupta5741 Cleveland street,Suite 120, VA beach, VA, USA 23462Tel: +1 (757) 343–3258Email: info@marketsandata.comWebsite: https://www.marketsandata.com
